Nektar Therapeutics (NASDAQ:NKTR) went down by -0.98% from its latest closing price when compared to the 1-year high value of $28.60 and move down -49.35%, while NKTR stocks collected -0.96% of loss with the last five trading sessions. Press Release reported on 08/12/20 that Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
Nektar Therapeutics (NASDAQ:NKTR) Worth an Investment?
Nektar Therapeutics (NASDAQ: NKTR) The 36 Months beta value for NKTR stocks is at 1.77, while 9 of the analysts out of 15 who provided ratings for Nektar Therapeutics stocks as a “buy” while 0 as overweight, 6 rated it as hold and 0 as sell. The average price we get from analysts is $31.77 which is $12.21 above current price. NKTR currently has a short float of 14.88% and public float of 177.59M with average trading volume of 946.05K shares.
NKTR Market Performance
NKTR stocks went down by -0.96% for the week, with the monthly drop of -13.27% and a quarterly performance of -15.38%, while its annual performance rate touched 13.25%. The simple moving average for the period of the last 20 days is -4.45% for NKTR stocks with the simple moving average of -8.82% for the last 200 days.
Analysts’ Opinion on Nektar Therapeutics (NASDAQ:NKTR)
Many brokerage firms have already submitted their reports for NKTR stocks, with CFRA repeating the rating for NKTR shares by setting it to “Sell”. The predicted price for NKTR socks in the upcoming period according to CFRA is $30 based on the research report published on June 10, 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NKTR stock at the price of $26, previously predicting the value of $32. The rating they have provided for NKTR stocks is “Neutral” according to the report published on May 12, 2020.
The Benchmark Company gave “Buy” rating to NKTR stocks, setting the target price at $26 in the report published on April 22, 2020.
NKTR Stocks -13.31% Far from 50 Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, Nektar Therapeutics was unable to take a rebound, for now settling with -33.04% of loss for the given period.
The stock volatility was left at 3.07%, however, within the period of a single month, the volatility rate increased by 2.39%, while the shares sank at the distance of -12.64% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -18.30% lower at the present time.
In the course of the last 5 trading sessions, NKTR went down by -0.96%, which changed the moving average for the period of 200 days to the total of -1.44% of losses for the stock in comparison to the 20-day moving average settled at $19.90. In addition, Nektar Therapeutics saw -11.28% in overturn over the period of a single year with a tendency to cut further losses.
NKTR Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Nektar Therapeutics (NKTR), starting from Labrucherie Gil M, who sold 2,000 shares at the price of $19.68 back on Aug 18. After this action, Rushing now owns 237,249 shares of Nektar Therapeutics, valued at $39,360 with the latest closing price.
Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sold 26,200 shares at the value of $19.67 during a trade that took place back on Aug 17, which means that Zalevsky Jonathan is holding 296,315 shares at the value of $515,354 based on the most recent closing price.
NKTR Stock Fundamentals
The current profitability levels are settled at -383.92 for the present operating margin and +74.25 for gross margin. The net margin for Nektar Therapeutics stands at -384.47. Total capital return value is set at -22.67, while invested capital returns managed to touch -24.34. Equity return holds the value -31.60%, with -22.80% for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 32.08 points for debt to equity in total, while total debt to capital is set at the value of 24.29. Total debt to assets is settled at the value of 22.80 with long-term debt to equity ratio rests at -9.49 and long-term debt to capital is 13.50.
The value for Enterprise to Sales is 25.33 with debt to enterprise value settled at 0.16. The receivables turnover for Nektar Therapeutics is 2.86 with the total asset turnover at the value of 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.